EXCLUSIVE: Nexalin Tells Benzinga 'Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer's Treatment'
Portfolio Pulse from Benzinga Newsdesk
Nexalin Technology has announced promising results from a trial indicating that its DIFS technology increases neural activity and blood flow in the hippocampus, potentially offering a new treatment avenue for Alzheimer's disease.
October 17, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nexalin Technology's DIFS technology has shown potential in increasing neural activity and blood flow in the hippocampus, which could be significant for Alzheimer's treatment.
The trial results suggest a significant advancement in Alzheimer's treatment, which could enhance Nexalin's market position and investor interest, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90